Prostate Cancer

Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.

An expert provides an overview of the types of androgen deprivation therapy (ADT) for mCSPC, other therapies that can be used in combination with ADT for treatment intensification and compares the safety and efficacy of the various regimens.

Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer (mCSPC).

Adding the PD-1 inhibitor to docetaxel led to a trend toward modest improvement in survival versus docetaxel alone; however, the results did not meet the trial’s threshold for statistical significance.

Dr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.

An expert’s brief commentary on follow-up strategies in patients receiving focal therapy, including monitoring for disease relapse or recurrence.

An experienced clinician shares his personal experience with preventing and managing side effects related to focal therapy in patients with clinically localized prostate cancer.

A focused discussion on how the availability and use of focal therapy technology has changed treatment paradigms and affected patient outcomes.

An oncologic urologist from the United Kingdom (UK) discusses the diffusion of focal therapy options for clinically localized prostate cancer in the United States and UK.

Dr Mark Emberton reviews safety and efficacy data supporting the use of focal therapy in patients with prostate cancer.

An in-depth discussion of emerging focal therapy options for clinically localized prostate cancer.

Insights on the drawbacks of older treatment approaches for clinically localized prostate cancer and how strategically implementing focal therapies may address remaining unmet needs and clinical challenges.

Dr Emberton provides a historical perspective of treatment options for clinically localized prostate cancer and discussed how use of these options has evolved over time.

A prostate cancer specialist breaks down prostate cancer staging and grading and identifies several shortcomings of established risk stratification methods for patients with clinically localized disease.

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci describes his approach to diagnosing patients with prostate cancer, highlighting prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) as critical to cancer detection.

The approval is based on findings from the phase 3 ARASENS trial.

The costimulatory bispecific antibody REGN5678 may alleviate resistance to immune checkpoint inhibition historically observed in prostate tumors.

Micro-ultrasound yielded comparable detection rates for prostate cancer as multiparametric magnetic resonance imaging.

“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.

The researchers combined machine learning and rule-based natural language processing to develop an algorithm that leveraged electronic health records to identify patients with nmCRPC.

A review of the currently available genomic testing options for patients with clinically localized prostate cancer and the NCCN and AUA/ASTRO recommendations based on risk group.

Stephen J. Freedland, MD, details which patient populations he orders genomic testing for, and how the tests can address clinical challenges in prostate cancer treatment.

The TAVT-45 formulation of abiraterone consists of granules for oral suspension and was created for patients with dysphagia who would have difficulty swallowing a tablet.

“Each patient is different, and some patients are more challenging than others in terms of placement,” says Jonathan E. Shoag, MD.

An expert urologist explains the potential for overtreatment of low-risk prostate cancer and undertreatment of high-risk prostate cancer and the potential consequences for patients.

A focused discussion on the challenges that urologists commonly face during the treatment decision-making process, and which factors typically inform treatment selection for clinically localized prostate cancer.

External beam radiotherapy plus or minus brachytherapy yielded lower rates of distant metastasis.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.

In this interview, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone agonists and antagonists in prostate cancer.